Injective
Why Injective is up 1.1% in the last hour
Analysis
Injective (INJ) rose 1.1% over the past hour likely on fresh ETF-related optimism after *The Block* reported that Injective CEO Eric Chen expects US INJ ETFs to launch sooner than 2027. The prospect of a nearer-term ETF timeline can boost short-term sentiment and buying interest, helping lift prices.
Contributing Factors (1)
Injective CEO Eric Chen expects US INJ ETFs to launch sooner than 2027
There are currently two ETF applications tied to INJ — the 21Shares Injective ETF and the Canary Staked INJ ETF.
Move Details
Explanation Confidence
High confidence in the explanation based on source reliability and timing.